Cost-effectiveness evaluation of abiraterone in the treatment of patients with castration-resistant prostate cancer who previously received docetaxel.

被引：0
|
作者：
Chopra, Akhil
Gluck, Stefan
Montero, Alberto J.
Avancha, Kiran Kumar Venkata Raja
Lopes, Gilberto
机构：
[1] Johns Hopkins Singapore Int Med Ctr, Singapore, Singapore
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[3] Univ Miami Hosp & Clin, Sylvester Comprehens Canc Ctr, Miami, FL USA
[4] Johns Hopkins Singapore, Singapore, Singapore
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15107
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy
    Rudakova, A. V.
    Meshkov, D. O.
    Mishugin, S. V.
    ONKOUROLOGIYA, 2014, 10 (03): : 73 - 77
  • [2] COST-EFFECTIVENESS EVALUATION OF ENZALUTAMIDE AND ABIRATERONE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PROGRESSING AFTER DOCETAXEL IN THE MEXICAN PUBLIC HEALTHCARE SYSTEM
    Gay, J. G.
    Schultz, N. M.
    Braun, S.
    VALUE IN HEALTH, 2018, 21 : S29 - S30
  • [3] Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients
    ten Ham, Renske M. T.
    van Nuland, Merel
    Vreman, Rick A.
    de Graaf, Laurens G.
    Rosing, Hilde
    Bergman, Andre M.
    Huitema, Alwin D. R.
    Beijnen, Jos H.
    Hovels, Anke M.
    VALUE IN HEALTH, 2021, 24 (01) : 121 - 128
  • [4] COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AS SECOND LINE TREATMENT FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER DOCETAXEL TREATMENT IN JAPAN
    Shibahara, H.
    Shiroiwa, T.
    Nakamura, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2013, 16 (07) : A415 - A416
  • [5] PSA surge in patients with castration-resistant prostate cancer receiving docetaxel.
    Tabata, Ken-ichi
    Satoh, Takefumi
    Matsumoto, Kazumasa
    Fujita, Tetsuo
    Iwamura, Masatsugu
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] COST-EFFECTIVENESS OF NIRAPARIB PLUS ABIRATERONE ACETATE AND PREDNISONE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Duru, E.
    Mattingly, T. J.
    Malone, D. C.
    VALUE IN HEALTH, 2024, 27 (06) : S62 - S62
  • [7] COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE AND SIPULEUCEL-T IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Gong, C. L.
    Hay, J. W.
    VALUE IN HEALTH, 2014, 17 (03) : A82 - A83
  • [8] COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE TREATMENT COMPARED WITH CABACITAXEL IN THE REPUBLIC OF PANAMA, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THAT HAVE FAILED TO CHEMOTHERAPY WITH DOCETAXEL
    Obando, C. A.
    Desanvicente-Celis, Z.
    Gonzalez, L.
    Muschett, D.
    Gonzalez, F.
    Goldberg, P.
    VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
  • [9] COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE TREATMENT COMPARED WITH CABACITAXEL IN DOMINICAN REPUBLIC, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THAT HAVE FAILED TO CHEMOTHERAPY WITH DOCETAXEL
    Obando, C. A.
    Desanvicente-Celis, Z.
    Gonzalez, L.
    Muschett, D.
    Gonzalez, F.
    Goldberg, P.
    VALUE IN HEALTH, 2014, 17 (07) : A635 - A635
  • [10] Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
    Schrader, Andres Jan
    Boegemann, Martin
    Ohlmann, Carsten-H.
    Schnoeller, Thomas J.
    Krabbe, Laura-Maria
    Hajili, Turkan
    Jentzmik, Florian
    Stoeckle, Michael
    Schrader, Mark
    Herrmann, Edwin
    Cronauer, Marcus V.
    EUROPEAN UROLOGY, 2014, 65 (01) : 30 - 36
12345